Thera 102
Alternative Names: Thera-102Latest Information Update: 11 Dec 2023
At a glance
- Originator Theratome Bio
- Class Eye disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Dry eyes
Most Recent Events
- 03 Nov 2023 Early research in Dry eyes in USA (Ophthalmic) (Theratome Bio pipeline, November 2023)